Desvenlafaxine

Desvenlafaxine
Clinical data
Pronunciation	/dɛsˌvɛnləˈfæksiːn/; des-ven-lə-FAK-seen
Trade names	Pristiq, Desfax, Ellefore, others
Other names	O-desmethylvenlafaxine, WY-45233
AHFS/Drugs.com	Monograph
MedlinePlus	a608022
License data	US DailyMed: Desvenlafaxine;
Pregnancy; category	AU: B2;
Routes of; administration	By mouth
ATC code	N06AX23 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Bioavailability	80%
Protein binding	Low (30%)
Metabolism	CYP2C19, CYP3A4, (CYP2D6 is not involved)
Elimination half-life	11 h
Excretion	45% excreted unchanged in urine
Identifiers
	IUPAC name (RS)-4-[2-dimethylamino-1-(1-hydroxycyclohexyl); ethyl]phenol;
CAS Number	93413-62-8 ;
PubChem CID	125017;
IUPHAR/BPS	7158;
DrugBank	DB06700 ;
ChemSpider	111300 ;
UNII	NG99554ANW;
KEGG	D07793 ;
ChEBI	CHEBI:83527 ;
ChEMBL	ChEMBL1118 ;
CompTox Dashboard (EPA)	DTXSID40869118 ;
ECHA InfoCard	100.149.615
Chemical and physical data
Formula	C16H25NO2
Molar mass	263.381 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2;
	InChI InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 ; Key:KYYIDSXMWOZKMP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat depression.^[4] It is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth.^[4] It is recommended that the need for further treatment be occasionally reassessed.^[4] Studies have shown similar effectiveness compared to its parent compound venlafaxine.^[5]^[6] While other studies have shown it to be either less effective^[7] or more effective^[8] than venlafaxine.

Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems.^[4] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.^[4] There is a high risk of withdrawal syndrome which may occur if the dose is decreased or the medication is completely stopped.^[4]^[9] It is unclear if use during pregnancy or breastfeeding is safe.^[10]

Desvenlafaxine was approved for medical use in the United States in 2008.^[4] In Europe its application for use was denied in 2009.^[7] In 2022, it was the 208th most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[11]^[12]

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ "Mental health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^ "Desvenlafaxine Metabolic pathways". SMPBD. Retrieved February 3, 2022.
^ ^a ^b ^c ^d ^e ^f ^g "Desvenlafaxine Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
^ Cite error: The named reference :0 was invoked but never defined (see the help page).
^ Poitras V, Visintini S. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Oct 25. Key Findings. https://www.ncbi.nlm.nih.gov/books/NBK507131/
^ ^a ^b "Withdrawal Assessment Report for Dessvenlafaxime" (PDF). EMA. p. 3. Retrieved 22 March 2019.
^ Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, Armada Peláez B. Evaluación económica de la desvenlafaxina en el tratamiento de la depresión mayor en España [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain]. Rev Psiquiatr Salud Ment. 2016 Apr-Jun;9(2):87-96. Spanish. doi: 10.1016/j.rpsm.2015.08.002. Epub 2015 Oct 21. PMID: 26475204 https://pubmed.ncbi.nlm.nih.gov/26475204/
^ Miller K, King LM (10 July 2024). Begum J (ed.). "Withdrawal From Antidepressants: Symptoms, Causes, Treatments". WebMD. Retrieved 2024-09-02.
^ "Desvenlafaxine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 19 March 2019.
^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
^ "Desvenlafaxine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] "Mental health". Health Canada. 9 May 2018. Retrieved 13 April 2024.

[3] "Desvenlafaxine Metabolic pathways". SMPBD. Retrieved February 3, 2022.

[AHFS2019-4] ^ ^a ^b ^c ^d ^e ^f ^g "Desvenlafaxine Succinate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.

[:0-5] Cite error: The named reference :0 was invoked but never defined (see the help page).

[6] Poitras V, Visintini S. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Oct 25. Key Findings. https://www.ncbi.nlm.nih.gov/books/NBK507131/

[EMA2009-7] "Withdrawal Assessment Report for Dessvenlafaxime" (PDF). EMA. p. 3. Retrieved 22 March 2019.

[8] Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, Armada Peláez B. Evaluación económica de la desvenlafaxina en el tratamiento de la depresión mayor en España [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain]. Rev Psiquiatr Salud Ment. 2016 Apr-Jun;9(2):87-96. Spanish. doi: 10.1016/j.rpsm.2015.08.002. Epub 2015 Oct 21. PMID: 26475204 https://pubmed.ncbi.nlm.nih.gov/26475204/

[9] Miller K, King LM (10 July 2024). Begum J (ed.). "Withdrawal From Antidepressants: Symptoms, Causes, Treatments". WebMD. Retrieved 2024-09-02.

[10] "Desvenlafaxine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 19 March 2019.

[Top_300_of_2022-11] "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.

[12] "Desvenlafaxine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]